Lymphatic mapping and sentinel lymph node biopsy provide important prognostic data in patients with early stage melanoma and are crucial in guiding the management of the tumor. We report our experience with lymphatic mapping and sentinel lymph node biopsy in a group of patients with primary cutaneous melanoma and discuss recent concepts and controversies on its use.
Patients and Methods
A total of 111 patients with stage I-II AJCC primary cutaneous melanoma underwent lymphatic mapping and sentinel lymph node biopsy from December 1999 through December 2004 using a standardized technique of preoperative lymphoscintigraphy and biopsy guided by blue dye injection in addition to a hand-held gamma probe. After removal, sentinel lymph nodes were submitted to serial sectioning and permanent preparations for histological and immunohistochemical examination. Complete lymph node dissection was performed only in patients with tumor-positive sentinel lymph nodes.
Results
Sentinel lymph nodes were identified and removed in all patients (detection rate of 100%), and metastases were found in 17 cases (15.3%). The incidence of metastasis in sentinel lymph nodes was 2.1%, 15.9%, 35.2%, and 41.6% for melanomas < or 1.0, 1.01-2.0, 2.01-4.0, and > 4.0 mm in thickness, respectively. Complete lymph node dissection was performed in 15 of 17 patients with positive sentinel lymph nodes, and metastases in non-sentinel lymph nodes were detected in only 2 cases (11.7%). Recurrences were more frequently observed in patients with a positive than in those with negative sentinel lymph node (41.1% vs 5.3% at a median follow-up of 31.5 months, P<0.001). The false-negative rate was 2.1%.
Conclusions
Our study confirms that lymphatic mapping and sentinel lymph node biopsy allow accurate staging and yield relevant prognostic information in patients with early stage melanoma.
MortonD.L., WenD.R., WongJ.H.: Technical details of intraoperative lymphatic mapping for early stage melanoma.Arch Dermatol,127: 392–399, 1992.
2.
GershenwaldJ.E., ColomeM.I., LeeJ.E.: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.J Clin Oncol,16: 2253–2260, 1998.
3.
GershenwaldJ.E., ThompsonW., MansfieldP.F., LeeJ.E., ColomeM.I., TsengC.H., LeeJ.J., BalchC.M., ReintgenD.S., RossM.I.: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.J Clin Oncol,17: 976–983, 1999.
4.
ThompsonJ.F., UrenR.F.: Lymphatic mapping and sentinel node biopsy for melanoma.Expert Rev Anticancer Ther,1: 446–452, 2001.
5.
JohnsonT.M., BradfordC.R., GruberS.B.: Staging workup, sentinel node biopsy, and follow-up tests for melanoma.Arch Dermatol,140: 107–113, 2004.
6.
BalchC.M., SoongS.J., GershenwaldJ.E.: Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System.J Clin Oncol,19: 3622–3634, 2001.
7.
BalchC.M., BuzaidA.C., SoongS.J.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.J Clin Oncol,19: 3635–3648, 2001.
8.
BalchC.M., SoongS.J., AtkinsM.B.: An evidence-based staging system for cutaneous melanoma.Ca Cancer J Clin,54: 131–149, 2004.
9.
LandiG., PolverelliM., MoscatelliG.: Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases.J Eur Acad Dermatol Venereol,14: 35–45, 2000.
10.
LeongS.P.: The role of sentinel lymph nodes in malignant melanoma.Surg Clin North Am,80: 1741–1757, 2000.
11.
HarlowS.P., KragD.N., AshikagaT.: Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study.Melanoma Res,11: 45–55, 2001.
12.
CascinelliN., BelliF., SantinamiM.: Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience.Ann Surg Oncol,7: 469–474, 2000.
13.
PerrottR.E., GlassL.F., ReintgenD.S.: Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma.J Am Acad Dermatol,49: 567–588, 2003.
14.
CookM.G., GreenM.A., AndersonB., EggermontA.M., RuiterD.J., SpatzA., KissinM.W., PowellB.W., EORTC Melanoma Group: The development of optimal pathological assessment of sentinel lymph nodes for melanoma.J Pathol,200: 314–319, 2003.
15.
CarlsonJ.A., RossJ.S., SlominskiA.: Molecular diagnostics in melanoma.J Am Acad Dermatol,52: 743–775, 2005.
16.
AzzolaM.F., ShawH.M., ThompsonJ.F.: Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.Cancer,97: 1488–1498, 2003.
17.
KesmodelS.B., KarakousisG.C., BotbylJ.D.: Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.Ann Surg Oncol,12: 449–459, 2005.
18.
UrenR.F., Howman-GilesR., ThompsonJ.F.: Interval nodes: the forgotten sentinel nodes in patients with melanoma.Arch Surg,135: 1168–1172, 2000.
FincherT.R., O'BrienJ.C., McCarthyT.M.: Patterns of drainage and recurrence following sentinel lymph node biopsy for cutaneous melanoma of the head and neck.Arch Otolaryngol Head Neck Surg,130: 844–848, 2004.
21.
CarlsonG.W., MurrayD.R., LylesR.H.: Sentinel lymph node biopsy in the management of cutaneous head and neck melanoma.Plast Reconstr Surg,115: 721–728, 2005.
22.
EssnerR., ConfortiA., KellyM.C.: Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early stage melanoma.Ann Surg Oncol,6: 442–449, 1999.
23.
BachterD., MichlC., BuchelsH.: The predictive value of the sentinel lymph node in malignant melanomas.Recent Results Cancer Res,158: 129–136, 2001.
24.
ClaryB.M., BradyM.S., LewisJ.J.: Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence.Ann Surg,233: 250–258, 2001.
25.
YeeV.S., ThompsonJ.F., McKinnonJ.G.: Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy.Ann Surg Oncol,12: 429–439, 2005.
26.
MortonD.L., HoonD.S., CochranA.J.: Lymphatic mapping and sentinel lymphadenectomy for early stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.Ann Surg,238: 538–550, 2003.
27.
CarlsonJ.A., SlominskiA., LinetteG.P.: Biomarkers in melanoma: staging, prognosis and detection of early metastases.Expert Rev Mol Diagn,3: 303–330, 2003.
28.
WangX., HellerR., VanVoorhisN.: Detection of submicro-scopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma.Ann Surg,220: 768–774, 1994.
29.
BlahetaH-J, SchittekB., BreuningerH.: Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry.Int J Cancer,79: 318–323, 1998.
30.
DavidsV., KidsonS.H., HanekomG.S.: Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node.Melanoma Res,13: 313–324, 2003.
31.
DavidsV., KidsonS.H., HanekomG.S.: Accurate molecular detection of melanoma nodal metastases: an assessment of mul-timarker assay specificity, sensitivity, and detection rate.Mol Pathol,56: 43–51, 2003.
32.
McMasterK.M., WongS.L., EdwardsM.J.: Frequency of non-sentinel lymph node metastasis in melanoma.Ann Surg Oncol,9: 137–141, 2002.
33.
CarlsonG.W., MurrayD.R., LylesR.H.: The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance?Ann Surg Oncol,10: 575–581, 2003.
34.
WagnerJ.D., GordonM.S., ChuangT.Y.: Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma.Cancer,89: 453–462, 2000.
35.
StarzH., BaldaB.R., KramerK.U.: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma.Cancer,91: 2110–2121, 2001.
36.
DewarD.J., NewellB., GreenM.A.: The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement.J Clin Oncol,22: 3345–3349, 2004.
37.
CochranA.J., WenD.R., HuangR.R.: Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node.Mod Pathol,17: 747–755, 2004.
38.
ThomasJ.M., ClarkM.A.: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma.Eur J Surg Oncol,30: 686–691, 2004.
39.
ThomasJ.M., ClarkM.A.: Sentinel lymph node biopsy: not yet standard of care for melanoma.BMJ,329: 170, 2004.
40.
Gallegos-HernandezJ.F., NiewegO.E., TanisP.J.: Biopsy of sentinel node in melanoma is not yet the standard treatment.Gac Med Mex,139: 449–452, 2003.
41.
EstourgieS.H., NiewegO.E., KroonB.B.: High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma.Br J Surg,91: 1370–1371, 2004.
42.
MolenkampB.G., Statius MullerM.G., VuylstekeR.J.: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma.Eur J Surg Oncol,31: 211–212, 2005.
43.
Russell-JonesR., HealyC., PowellA.M.: Completion lymphadenectomy may not increase in-transit disease in malignant melanoma.BMJ,329: 1288–1289, 2004.
44.
KretschmerL., BeckmannI., ThomasK.M.: Sentinel lymphon-odectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas.Eur J Cancer,41: 531–538, 2005.
45.
Russell-JonesR., PowellA.M., AclandK.: The chances of a patient with melanoma developing in-transit disease are doubled by undergoing sentinel lymph node biopsy (SLNB).Eur J Surg Oncol,31: 210–211, 2005.
46.
PawlikT.M., RossM.I., ShawH.M., ThompsonJ.F., GershenwaldJ.E.: Elective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark.Eur J Surg Oncol,31: 323–324, 2005.
47.
VeronesiU., AdamusJ., BandieraD.C.: Inefficacy of immediate node dissection in stage I melanoma of the limbs.N Engl J Med,297: 627–630, 1977.
48.
BalchC.M., SoongS.J., BartolucciA.A.: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.Ann Surg,224: 255–263, 1996.
49.
CascinelliN., MorabitoA., SantinamiM.: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme.Lancet,351: 793–796, 1998.
50.
KretschmerL., HilgersR., MohrleM.: Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease.Eur J Cancer,40: 212–218, 2004.
